ReviewExpert review of anti-infective therapy2009
Novel approaches in fighting herpes simplex virus infections.
Review in Expert review of anti-infective therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.
- Supportive care and antiviral treatments in primary herpetic gingivostomatitis: a systematic review.Clinical oral investigations · 2023Pooled it
- Clinical efficacy of oral ganciclovir for prophylaxis and treatment of recurrent herpes simplex keratitis.Chinese medical journal · 2015Trial
- Unique Attributes of Guinea Pigs as New Models to Study Ocular Herpes Pathophysiology and Recurrence.Investigative ophthalmology & visual science · 2023Article
- Review
- Viral Infection and Antiviral Treatments in Ocular Pathologies.Microorganisms · 2022Review
- In vitro evaluation of antiviral activity of Shouchella clausii probiotic strain and bacterial supernatant against herpes simplex virus type 1.Archives of microbiology · 2022Article
- Simple and rapid high-throughput assay to identify HSV-1 ICP0 transactivation inhibitors.Antiviral research · 2021Article
- Synthesis and Evaluation of Some Uracil Nucleosides as Promising Anti-Herpes Simplex Virus 1 Agents.Molecules (Basel, Switzerland) · 2021Article
- Alphaherpesvirus Vaccines.Current issues in molecular biology · 2021Review
- Potential Synergistic Action of Bioactive Compounds from Plant Extracts against Skin Infecting Microorganisms.International journal of molecular sciences · 2020Review
- Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections.Microorganisms · 2019Review
- Discovery of Small-Molecule Inhibitors Targeting the E3 Ubiquitin Ligase Activity of the Herpes Simplex Virus 1 ICP0 Protein Using anJournal of virology · 2019Article
- A Preclinical Model for Studying Herpes Simplex Virus Infection.The Journal of investigative dermatology · 2019Article
- Article
- Inhibition of Herpes Simplex Virus-1 Entry into Human Cells by Nonsaccharide Glycosaminoglycan Mimetics.ACS medicinal chemistry letters · 2018Article
- Article
- In vitro studies of the antiherpetic effect of photodynamic therapy.Lasers in medical science · 2016Article
- New strategies against drug resistance to herpes simplex virus.International journal of oral science · 2016Review
- Corilagin Protects Against HSV1 Encephalitis Through Inhibiting the TLR2 Signaling Pathways In Vivo and In Vitro.Molecular neurobiology · 2015Article
- Dynasore disrupts trafficking of herpes simplex virus proteins.Journal of virology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The development of novel strategies to eradicate herpes simplex virus (HSV) is a global public health priority. While acyclovir and related nucleoside analogues provide successful modalities for treatment and suppression, HSV remains highly prevalent worldwide and is a major cofactor fueling the HIV epidemic. HSV is the predominant cause of genital ulcerative disease, and neonatal and sporadic infectious encephalitis. Asymptomatic shedding, which occurs more frequently than previously appreciated, contributes to viral transmission. Acyclovir resistance may be problematic for immunocompromised patients and highlights the need for new safe and effective agents. Ideally, vaccines to prevent infection, drugs to inhibit the establishment of or reactivation from latency, or vaginal microbicides to prevent sexual and perinatal transmission are needed to control the epidemic. This review summarizes current therapeutic options and strategies in development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.